Results 1 - 10 of 96 : 1 2 3 4 5 6 7 8 9 Next
Eli Lilly's Dose of Disclosure
The pharmaceutical pledges public reports of its dealings with doctors.
Merck's shareholders get their case reinstated.
Cell Genesys Takes a Body Blow
Can it make a comeback after a failed cancer study of its lead drug?
Johnson & Johnson Gets Rejected
The FDA rejects Johnson & Johnson's antibiotic.
The Growth Stocks You Should Be Buying
Go hunting for misunderstood multibaggers in the making.
All it takes is a little flipping.
Low-Rated Stocks That Deserve Your Support
Shareholder-friendly stocks that have been marked to underperform the market.
The Buying Opportunity You Won't Want to Miss
One market is about to get a whole lot more interesting.
Great Call on Akamai! What's Next?
This Fool made a great call on Akamai -- there are other stocks he thinks you should look at.
More Good News About Cancer Vaccines
Pfizer's deal with Avant for an immunotherapy for brain cancer is promising.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK